Skip to main content

BeOne Medicines Ltd. (ONC) Stock Analysis

Falling Knife setup

Buy WaitModerate Confidence

Healthcare · Biotechnology

Earnings in 6 days (2026-05-06). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Wait for pullback to $293.95. Weak momentum — blocks BUY_NOW at $296.43. Engine's entry $293.95 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: BRUKINSA; Earnings in 6 days (event risk).

BeOne Medicines is a global oncology company that generated approximately $5.3 billion in total revenue in 2025, a 40.2% increase year-over-year. BRUKINSA, its BTK inhibitor approved in over 75 markets, became the global market leader across B-cell malignancies and generated... Read more

$296.43+25.2% A.UpsideScore 6.2/10#11 of 158 Biotechnology
Entry $293.95(Support Atr Sticky)Stop $278.77Target $367.38(analyst − 10%)A.R:R 4.7:1Setup A.R:R 5.9:1
Analyst target$408.20+37.7%26 analysts
$367.38our TP
$296.43price
$408.20mean
$498

Wait for pullback to $293.95. Weak momentum — blocks BUY_NOW at $296.43. Engine's entry $293.95 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: BRUKINSA; Earnings in 6 days (event risk). Chart setup: Death cross, below all MAs, RSI 40, MACD bearish. Maintain position. Not compelling to add more. | News modifier +1 (HOLD_IF_HOLDING → STRONG_BUY_WAIT) Score 6.2/10, moderate confidence.

Passes 4/6 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and earnings proximity 6d<=7d. Suitability: moderate.

Val5.5Qual6.5Grw10.0Mom1.3Sent8.6Ins5.0Peer4.2Tech7.3Risk6.56.2OVERALL

Thesis

Rewards
Strong earnings beat streak (3/4)
Positive news sentiment (+0.56)
Strong growth profile
Risks
Concentration risk — Product: BRUKINSA
Earnings in 6 days (event risk)
Negative momentum

Key Metrics

P/E (TTM)117.7
P/E (Fwd)30.5
Mkt Cap$32.3B
EV/EBITDA718.6
Profit Mgn5.4%
ROE7.5%
Rev Growth32.8%
Beta0.54
DividendNone
Rating analysts15

Quality Signals

Piotroski F9/9

Options Flow

P/C1.08bearish
IV50%elevated
Max Pain$260-12.3% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHProductBRUKINSA
    10-K Item 1A: 'BRUKINSA generated $3.9 billion in sales in 2025'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker·2 ceiling hits

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd
0.0
Volume
0.0
Obv
1.0
Ma Position
2.2
Rsi
3.5
Volume distribution (falling OBV)Below 200-MA but MA still rising (+2.1%/30d) — pullback in uptrend, not confirmed weakness
GatesMomentum 1.3<4.5EARNINGS PROXIMITY 6d<=7dA.R:R 4.7 ≥ 1.5Insider activity: OKNo SEC red flagsSEMI CYCLE PEAK CLEARFalling KnifeSuitability: Moderate
RSI
40 · Neutral
↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $289.54Resistance $328.39

Price Targets

$279
$294
$367
A.Upside+23.9%
A.R:R4.7:1
Setup A.R:R (at entry)5.9:1

Position Sizing

ConvictionMedium conviction
Suggested %0.5%
Max %1%
RegimeCautious

Risk Alerts

! NEWS_MOD=+1: HOLD_IF_HOLDING → STRONG_BUY_WAIT
! Momentum score 1.3/10 — below 4.5 minimum
! EARNINGS_PROXIMITY:6d<=7d

Earnings

B
B
B
M
3/4 beats
Next Earnings2026-05-06 (6d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is ONC stock a buy right now?

Wait for pullback to $293.95. Weak momentum — blocks BUY_NOW at $296.43. Engine's entry $293.95 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: BRUKINSA; Earnings in 6 days (event risk). Chart setup: Death cross, below all MAs, RSI 40, MACD bearish. Maintain position. Not compelling to add more. | News modifier +1 (HOLD_IF_HOLDING → STRONG_BUY_WAIT) Target $367.38 (+23.9%), stop $278.77 (−6.3%), Setup A.R:R 5.9:1. Score 6.2/10, moderate confidence.

What is the ONC stock price target?

Take-profit target: $367.38 (+25.2% upside). Target $367.38 (+23.9%), stop $278.77 (−6.3%), Setup A.R:R 5.9:1. Stop-loss: $278.77.

What are the risks of investing in ONC?

Concentration risk — Product: BRUKINSA; Earnings in 6 days (event risk); Negative momentum.

Is ONC overvalued or undervalued?

BeOne Medicines Ltd. trades at a P/E of 117.7 (forward 30.5). TrendMatrix value score: 5.5/10. Verdict: Buy (Wait for Entry).

What do analysts say about ONC?

15 analysts cover ONC with a consensus score of 4.1/5. Average price target: $408.

What does BeOne Medicines Ltd. do?BeOne Medicines is a global oncology company that generated approximately $5.3 billion in total revenue in 2025, a...

BeOne Medicines is a global oncology company that generated approximately $5.3 billion in total revenue in 2025, a 40.2% increase year-over-year. BRUKINSA, its BTK inhibitor approved in over 75 markets, became the global market leader across B-cell malignancies and generated $3.9 billion in 2025 sales. The company reported net income of $286.9 million and positive free cash flow of $941.7 million.

Related stocks: INCY (Incyte Corporation) · CPRX (Catalyst Pharmaceuticals, Inc.) · HALO (Halozyme Therapeutics, Inc.) · ACAD (ACADIA Pharmaceuticals Inc.) · ALNY (Alnylam Pharmaceuticals, Inc.)